|
|
||||||||
F508 mutation is an independent risk factor
Depts of 1 Nutrition, 2 Endocrinology and Diabetes, 3 Allergy, Immunology and Respiratory Medicine, Alfred Hospital, 4 Dept of Epidemiology and Preventive Medicine, Monash University, and 5 Depts of Diabetes and Endocrinology, and Medicine, Royal Melbourne Hospital, Melbourne, Australia
CORRESPONDENCE: S. J. King, Nutrition Dept, Alfred Hospital, Commercial Road, Melbourne, Victoria 3004, Australia. Fax: 61 392763029. E-mail: susannah.king@med.monash.edu.au
Keywords: Bone mineral density, cystic fibrosis, genotype, nutrition, osteoporosis
Received: April 28, 2004
Accepted August 24, 2004
The aim of this cross-sectional study was to determine the prevalence and identify determinants of reduced bone mineral density (BMD) in adults with cystic fibrosis (CF).
Adults (88) with CF (mean±SD age 29.9±7.7 yrs; forced expiratory volume in one second (FEV1) 58.2±21.5% of the predicted value) were studied. BMD at the lumbar spine (LS) and femoral neck (FN) and body composition were measured using dual-energy X-ray absorptiometry. Blood and urine were analysed for hormones, bone turnover markers, and the cytokines tumour necrosis factor-
BMD Z-scores were 0.58±1.30 (mean±SD) at the LS and 0.24±1.19 at the FN. Z-scores of <2.0 were found in 17% of subjects. Subjects who were homozygous or heterozygous for the
In conclusion, reduced bone mineral density in cystic fibrosis is associated with a number of factors, including
, and interleukin-6 and -1ß. FEV1 (% pred); CF genotype; malnutrition; history of growth, development or weight gain delays; and corticosteroid use were analysed.
F508 mutation exhibited significantly lower Z-scores than those with no
F508 allele. Multiple linear regression showed that the
F508 genotype and male sex were independently associated with lower BMD at both sites. Other factors also independently associated with lower BMD included malnutrition, lower 25-hydroxyvitamin D level, lower fat-free mass and lower FEV1 (% pred).
F508 genotype, male sex, greater lung disease severity and malnutrition.
This article has been cited by other articles:
![]() |
C. K. Haston, W. Li, A. Li, M. Lafleur, and J. E. Henderson Persistent Osteopenia in Adult Cystic Fibrosis Transmembrane Conductance Regulator-deficient Mice Am. J. Respir. Crit. Care Med., February 1, 2008; 177(3): 309 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. F Shead, C. S Haworth, A. M Condliffe, D. J McKeon, M. A Scott, and J. E Compston Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone Thorax, July 1, 2007; 62(7): 650 - 651. [Full Text] [PDF] |
||||
![]() |
I. Sermet-Gaudelus, J. C. Souberbielle, J. C. Ruiz, S. Vrielynck, B. Heuillon, I. Azhar, A. Cazenave, E. Lawson-Body, F. Chedevergne, and G. Lenoir Low Bone Mineral Density in Young Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 951 - 957. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Treszl, K. Nemeth, I. Kocsis, B. Vasarhelyi, G. Fekete, T. Tulassay, and M. Szathmari The prevalence of {Delta}F508 in primary osteoporotic patients Eur. Respir. J., August 1, 2005; 26(2): 362 - 363. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |